Ingrid A. Mayer
在学术界和临床实践中做了20年的肿瘤学家, 我目前担任的职位是乳腺癌和妇科癌症全球临床战略主管，这使我能够开拓和扩展新的全球转化研究和创新临床试验开发，从而加速澳门在线赌城娱乐卓越关键领域的现有和新型药物的批准, tumour resistance/targeted therapies, DNA damage response, antibody-drug conjugates and immuno-oncology.
我的总体愿景是促进乳腺癌和妇科癌症的范式转换和实践改变治疗，以降低死亡率, morbidity and health disparities, 以及解决乳腺癌和妇科癌症医疗领域的关键知识空白.
Before joining AstraZeneca, 我在范德比尔特大学医学中心担任医学教授和英格拉姆癌症研究教授18年, 在我的职业生涯中，我成功地指导过研究员和初级教员. 作为一名训练有素的乳腺癌医学肿瘤学家，我为数千名患者提供了尖端的护理. I have extensive experience with novel therapeutics in phase I, II and III clinical trials, 曾担任超过90项临床试验的首席研究员，从I期到III期. 我在乳腺癌的转化研究主要集中在确定治疗耐药的靶向途径和机制, 得到了NCI的认可和资助(乳腺癌中的K23和孢子), SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation, and published in more than 135 peer-reviewed journals. I have chaired, 美国许多国家和国际卫生服务癌症领导委员会的共同主席或成员, such as ECOG-ACRIN Breast Core Committee, 国家综合癌症网络(NCCN)乳腺癌专家小组, 转化性乳腺癌研究联盟(TBCRC)等.
从床到床的研究使澳门第一赌城在线娱乐改变了癌症治疗的模式和实践, making treatments more effective and patient-centred. 我对澳门第一赌城在线娱乐正在进行的有助于降低死亡率的研究感到兴奋, morbidity and health disparities for cancer patients
2018-2022
2013-2021
2011-2021
CURRENT ROLE
2022
2021
2021
Featured publications
基于铂的化疗与卡培他滨在新辅助化疗后残余三阴性乳腺癌患者中的随机III期术后试验:ECOG-ACRIN EA1131
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. 基于铂的化疗与卡培他滨在新辅助化疗后残余三阴性乳腺癌患者中的随机III期术后试验:ECOG-ACRIN EA1131. J Clin Oncol. 2021 Aug 10;39(23):2539-2551. doi: 10.1200/JCO.21.00976. Epub 2021 Jun 6. PubMed PMID: 34092112; PubMed Central PMCID: PMC8577688.
指导乳腺癌辅助治疗使用的临床和基因组风险
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. 指导乳腺癌辅助治疗使用的临床和基因组风险. N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3. PubMed PMID: 31157962; PubMed Central PMCID: PMC6709671.
Alpelisib治疗pik3ca突变、激素受体阳性的晚期乳腺癌
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D. Alpelisib治疗pik3ca突变、激素受体阳性的晚期乳腺癌. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. PubMed PMID: 31091374.
新辅助来曲唑加Alpelisib治疗激素受体阳性的II期随机研究, 人表皮生长因子受体2阴性乳腺癌(NEO-ORB)
Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL. 新辅助来曲唑加Alpelisib治疗激素受体阳性的II期随机研究, 人表皮生长因子受体2阴性乳腺癌(NEO-ORB). Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5. PubMed PMID: 30723140; PubMed Central PMCID: PMC6522303.
Sacituzumab Govitecan-hziy治疗难治性转移性三阴性乳腺癌
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy治疗难治性转移性三阴性乳腺癌. N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. PubMed PMID: 30786188.
乳腺癌21基因表达测定指导的辅助化疗
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. 乳腺癌21基因表达测定指导的辅助化疗. N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3. PubMed PMID: 29860917; PubMed Central PMCID: PMC6172658.
HER2-和her3突变型癌症患者的HER激酶抑制
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER2-和her3突变型癌症患者的HER激酶抑制. Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. PubMed PMID: 29420467; PubMed Central PMCID: PMC5808581.
A Randomized Phase II Neoadjuvant Study of Cisplatin, 紫杉醇加依维莫司或不加依维莫司治疗II/III期三阴性乳腺癌(TNBC):反应和长期结局与DNA损伤反应基因突变频率增加相关, TNBC Subtype, AR Status, and Ki67
Jovanović B*, Mayer IA*, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, 紫杉醇加依维莫司或不加依维莫司治疗II/III期三阴性乳腺癌(TNBC):反应和长期结局与DNA损伤反应基因突变频率增加相关, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7. PubMed PMID: 28270498; PubMed Central PMCID: PMC5540799. *equal authorship
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer
Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Jan 1;23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134. Epub 2016 Apr 28. PubMed PMID: 27126994; PubMed Central PMCID: PMC5085926.
乳腺癌21基因表达测定的前瞻性验证
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. 乳腺癌21基因表达测定的前瞻性验证. N Engl J Med. 2015 Nov.
泛磷酸肌醇-3激酶抑制剂布帕利西布联合来曲唑治疗雌激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的Ib期研究
Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. 泛磷酸肌醇-3激酶抑制剂布帕利西布联合来曲唑治疗雌激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的Ib期研究. J Clin Oncol. 2014 Apr 20;32(12):1202-9. doi: 10.1200/JCO.2013.54.0518. Epub 2014 Mar 24. PubMed PMID: 24663045; PubMed Central PMCID: PMC3986383.
Veeva ID: Z4-61020
Date of preparation: January 2024